HeimLSTA • NASDAQ
add
Lisata Therapeutics Inc
Við síðustu lokun
2,47 $
Dagbil
2,31 $ - 2,53 $
Árabil
1,87 $ - 4,20 $
Markaðsvirði
21,81 m. USD
Meðalmagn
11,54 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 1,00 m. | — |
Rekstrarkostnaður | 5,95 m. | -1,26% |
Nettótekjur | -4,61 m. | 14,07% |
Hagnaðarhlutfall | -461,00 | — |
Hagnaður á hvern hlut | -0,55 | 16,67% |
EBITDA | -4,91 m. | 17,90% |
Virkt skatthlutfall | 0,00% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 31,24 m. | -38,17% |
Heildareignir | 35,00 m. | -36,00% |
Heildarskuldir | 5,68 m. | -16,40% |
Eigið fé alls | 29,32 m. | — |
Útistandandi hlutabréf | 27,70 m. | — |
Eiginfjárgengi | 0,70 | — |
Arðsemi eigna | -33,80% | — |
Ávöxtun eigin fjár | -39,23% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -4,61 m. | 14,07% |
Handbært fé frá rekstri | -4,53 m. | -11,28% |
Reiðufé frá fjárfestingum | 1,39 m. | 124,31% |
Reiðufé frá fjármögnun | -96,00 þ. | -500,00% |
Breyting á handbæru fé | -3,30 m. | 66,45% |
Frjálst peningaflæði | -2,95 m. | -25,90% |
Um
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Stofnsett
1980
Höfuðstöðvar
Vefsvæði
Starfsfólk
26
